The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
List view / Grid view
Filter the results
Price caps and government regulations will not lower US healthcare costs, instead supply chain and drug pricing reforms are required, says a brief by medical economist.
The FDA has issued a statement to promote the development of complex generic drugs to ensure access for patients and healthy drug competition...
A Europe-wide policy covering the generic pharmaceuticals market would significantly boost growth in the sector, reveals a new report from Frost & Sullivan...